Basket | Login


SS2 Changing how we communicate about Alzheimer’s disease

Detailed programme and abstracts

SS2 Changing how we communicate about Alzheimer’s disease


Previous attempts to bring new drugs for Alzheimer’s disease to the market have been disappointing despite a high level of investment. However, the realisation that Alzheimer’s disease is a progressive disorder and that early intervention may be more effective has led to research efforts being focused on prevention. The goal of the EPAD project is therefore the prevention of Alzheimer’s dementia in people with evidence of the disease (such as biomarker abnormalities as identified by specific tests), who still may have little or no complaints or clinical symptoms.

This new understanding of Alzheimer’s disease as a continuum where brain changes may precede cognitive symptoms and the occurrence of dementia by up to 20 years is still little understood by the wider dementia community and the general public. The aim of this interactive symposium is therefore to present the scientific rationale for this new understanding of Alzheimer’s disease and to discuss with the audience the ethical challenges posed by this new definition, as well as the public’s perceptions and attitudes towards predictive testing and disclosure of risk.



Last Updated: Monday 12 September 2016